Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8744992 | Clinical Microbiology and Infection | 2017 | 30 Pages |
Abstract
Health systems have a finite and decreasing resource, decision makers currently do not have necessary evidence to assess whether AMS programmes provide sufficient benefits. Although the evidence-base of the cost-effectiveness of AMS is increasing, it remains inadequate for investment decision-making. Robust health economics research needs to be completed to enhance the generalizability and usability of cost-effectiveness results.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
N.R. Naylor, N. Zhu, M. Hulscher, A. Holmes, R. Ahmad, J.V. Robotham,